Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study

Abstract

NCT00921960.

Biomarker‐based risk prediction in the community

“…The NNT to prevent one cardiovascular event over a period of time is increasingly used in interpreting the findings of preventative clinical trials as it incorporates the relative risk reduction from a therapeutic intervention as well as the incidence of the outcome in the relevant population and illustrates the clinical and economic impact of prevention strategies . For example, the NNT with atorvastatin (20 mg) to prevent one fatal or non‐fatal coronary or cerebral vascular event in 10 years in patients with a 10‐year cardiovascular risk of ≥7.5% varies from 6 to 69 depending on the pretreatment cardiovascular risk score and low‐density lipoprotein cholesterol (LDL) level .…”

New‐onset heart failure in the STOP‐HF programme. Natriuretic peptide defines and tracks risk and enables earlier diagnosis of heart failure

“…The St Vincent's screening TO Prevent‐Heart Failure (STOP‐HF) programme, a clinically proven and cost‐effective approach to HF prevention, offers a valuable opportunity to obtain insight into risk stratification and new‐onset HF over time, based on longitudinal follow‐up of an at‐risk cohort. This programme, an extension of the STOP‐HF trial, utilises B‐type natriuretic peptide (BNP)‐based risk stratification and collaborative care between community physicians and specialist cardiology services to optimise risk factor control, prevent HF and monitor for the onset of symptomatic HF.…”

How peptide technology has improved costs and outcomes in patients with heart failure

“…More recently, Ledwidge et al [24] used data from the STOP-HF (St Vincent's Screening TO Prevent Heart Failure intervention) study in which 1054 patients were randomized to either a control group where the patients with suspected HF received the standard of care (assessment from a primary health-care professional, a nurse and referral to a cardiologist), or in the intervention group which comprised NP screening. A cost-utility and a cost-consequences analysis were conducted with the number of HF/left ventricular dysfunction and major adverse cardiac events (MACE), being the main outcomes evaluated.…”